Cooper JM - Search Results

1

Inclusion formation in Huntington's disease R6/2 mouse muscle cultures.

Orth M, Cooper JM, Bates GP, Schapira AH. Orth M, et al. Among authors: cooper jm. J Neurochem. 2003 Oct;87(1):1-6. doi: 10.1046/j.1471-4159.2003.02009.x. J Neurochem. 2003. PMID: 12969246 Free article.

2

Clinical correlates of mitochondrial function in Huntington's disease muscle.

Turner C, Cooper JM, Schapira AH. Turner C, et al. Among authors: cooper jm. Mov Disord. 2007 Sep 15;22(12):1715-21. doi: 10.1002/mds.21540. Mov Disord. 2007. PMID: 17557337

3

Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis.

Chau KY, Ching HL, Schapira AH, Cooper JM. Chau KY, et al. Among authors: cooper jm. J Neurochem. 2009 Aug;110(3):1005-13. doi: 10.1111/j.1471-4159.2009.06191.x. Epub 2009 May 29. J Neurochem. 2009. PMID: 19493164 Free article.

4

Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse.

Tabrizi SJ, Workman J, Hart PE, Mangiarini L, Mahal A, Bates G, Cooper JM, Schapira AH. Tabrizi SJ, et al. Among authors: cooper jm. Ann Neurol. 2000 Jan;47(1):80-6. doi: 10.1002/1531-8249(200001)47:1<80::aid-ana13>3.3.co;2-b. Ann Neurol. 2000. PMID: 10632104

5

G209A mutant alpha synuclein expression specifically enhances dopamine induced oxidative damage.

Orth M, Tabrizi SJ, Tomlinson C, Messmer K, Korlipara LV, Schapira AH, Cooper JM. Orth M, et al. Among authors: cooper jm. Neurochem Int. 2004 Oct;45(5):669-76. doi: 10.1016/j.neuint.2004.03.029. Neurochem Int. 2004. PMID: 15234109

6

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms.

Gu M, Iravani MM, Cooper JM, King D, Jenner P, Schapira AH. Gu M, et al. Among authors: cooper jm. J Neurochem. 2004 Dec;91(5):1075-81. doi: 10.1111/j.1471-4159.2004.02804.x. J Neurochem. 2004. PMID: 15569251 Free article.

7

Pramipexole protects against MPTP toxicity in non-human primates.

Iravani MM, Haddon CO, Cooper JM, Jenner P, Schapira AH. Iravani MM, et al. Among authors: cooper jm. J Neurochem. 2006 Mar;96(5):1315-21. doi: 10.1111/j.1471-4159.2005.03625.x. Epub 2006 Feb 8. J Neurochem. 2006. PMID: 16464239 Free article.

8

Irreversible inhibition of mitochondrial complex I by 1-methyl-4-phenylpyridinium: evidence for free radical involvement.

Cleeter MW, Cooper JM, Schapira AH. Cleeter MW, et al. Among authors: cooper jm. J Neurochem. 1992 Feb;58(2):786-9. doi: 10.1111/j.1471-4159.1992.tb09789.x. J Neurochem. 1992. PMID: 1729421

9

Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.

Schapira AH, Mann VM, Cooper JM, Dexter D, Daniel SE, Jenner P, Clark JB, Marsden CD. Schapira AH, et al. Among authors: cooper jm. J Neurochem. 1990 Dec;55(6):2142-5. doi: 10.1111/j.1471-4159.1990.tb05809.x. J Neurochem. 1990. PMID: 2121905

10

Mitochondrial complex I deficiency in Parkinson's disease.

Schapira AH, Cooper JM, Dexter D, Clark JB, Jenner P, Marsden CD. Schapira AH, et al. Among authors: cooper jm. J Neurochem. 1990 Mar;54(3):823-7. doi: 10.1111/j.1471-4159.1990.tb02325.x. J Neurochem. 1990. PMID: 2154550

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

674 results

Search Page

Filters